source
- FDA signals upcoming rules for generative AI use in drug developmentThe FDA announced it intends to create regulatory guidance for the use of generative artificial intelligence in pharmaceutical research and development. The move follows growing interest in AI too…
- Bausch + Lomb to launch Phase 3 trial of dry‑eye drop after Phase 2 missBausch + Lomb announced plans to move its dual‑action dry‑eye drop into a Phase 3 study. The decision follows a Phase 2 trial that did not meet its primary endpoint. CEO Brent Saunders said the r…